Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
COPD
Interventions
DRUG

Revefenacin 175 mcg in 3 ML Inhalation Solution

Revefenacin

DRUG

Placebo inhalation solution QD

Placebo

Trial Locations (35)

10017

Inner Mongolia People's Hospital, Hohhot

10050

Affiliated Hospital of Inner Mongolia Medical College, Hohhot

100191

Peking University Third Hospital, Beijing

100730

Beijing Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

110004

Shengjing Hospital of China Medical University, Shenyang

130021

The First Bethune Hospital of Jilin University, Changchun

133000

Yanbian university hospital, Yanji

200031

Shanghai East Hospital, Shanghai

201299

Shanghai Pudong New Area People's Hospital, Shanghai

210009

Zhongda Hospital, Southeast University - Pulmonology, Nanjing

211100

Nanjing Jiangning Hospital, Nanjing

214023

Wuxi People's Hospital, Wuxi

214400

Jiangsu Jiangyin People's Hospital, Jiangyin

225001

Yangzhou First People's Hospital, Yangzhou

230061

Anhui Medical University - Hefei First People's Hospital, Hefei

300052

Tianjin Medical University General Hospital - Respiration, Tianjin

300192

The First Center hospital of Tianjin, Tianjin

310005

Xinhua Hostipal of Zhejiang Province, Hangzhou

313003

Huzhou Central Hospital, Huzhou

322199

Dongyang People's Hospital, Dongyang

330006

Jiangxi Provincial People's Hospital, Nanchang

Nanchang University - The Second Affiliated Hospital, Nanchang

332001

Sichuan University - West China Hospital, Chengdu

337000

Jiangxi Pingxiang People's Hospital, Pingxiang

410005

The First Hospital of Changsha, Changsha

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

510150

The Third Affiliated Hospital Of Guangzhou Medical University, Guangzhou

510180

Guangzhou First People's Hospital, Guangzhou

510260

The Second Affiliated Hospital Of Guangzhou Medical University, Guangzhou

524000

Affiliated Hospital of Guangdong Medical University, Guangzhou

570311

Hainan General Hospital, Haikou

830054

The First Affiliated Hospital of Xinjiang Medical University - Hospital, Ürümqi

014010

Inner Mongolia Baogang Hospital, Baotou

014017

The First Affiliated Hospital of Baotou Medical College - Respiration, Baotou

All Listed Sponsors
lead

Mylan Pharma UK Ltd.

INDUSTRY

NCT05046795 - Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD) | Biotech Hunter | Biotech Hunter